VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Apellis Pharmaceuticals
APLS
$3.55B
| $374K | 0.24% |
6,251
+2,950
| +89% | +$177K |
|
177
Amicus Therapeutics
FOLD
$2.46B
| $372K | 0.24% |
26,201
+3,324
| +15% | +$47.2K |
|
178
CION Investment
CION
$534M
| $368K | 0.23% |
32,533
-9,315
| -22% | -$105K |
|
179
BridgeBio Pharma
BBIO
$10.2B
| $367K | 0.23% |
9,084
-8,934
| -50% | -$361K |
|
180
ADMA Biologics
ADMA
$4.03B
| $365K | 0.23% |
80,743
+2,519
| +3% | +$11.4K |
|
181
Acadia Pharmaceuticals
ACAD
$4.26B
| $364K | 0.23% |
11,625
-980
| -8% | -$30.7K |
|
|
BPMC
182
DELISTED
Blueprint Medicines
BPMC
| $359K | 0.23% |
3,892
-1,287
| -25% | -$119K |
|
|
ITCI
183
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $358K | 0.23% |
4,994
+271
| +6% | +$19.4K |
|
184
Axsome Therapeutics
AXSM
$6.25B
| $354K | 0.22% |
4,452
+690
| +18% | +$54.9K |
|
185
Neurocrine Biosciences
NBIX
$14.3B
| $354K | 0.22% |
2,688
-539
| -17% | -$71K |
|
186
Insmed
INSM
$30.7B
| $350K | 0.22% |
11,295
-4,482
| -28% | -$139K |
|
187
Rhythm Pharmaceuticals
RYTM
$6.78B
| $349K | 0.22% |
7,597
-9,596
| -56% | -$441K |
|
188
Immunocore
IMCR
$1.87B
| $349K | 0.22% |
5,104
-161
| -3% | -$11K |
|
189
Main Street Capital
MAIN
$5.95B
| $348K | 0.22% |
8,054
-3,095
| -28% | -$134K |
|
|
DCF
190
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $348K | 0.22% |
42,673
-22,420
| -34% | -$183K |
|
191
Tarsus Pharmaceuticals
TARS
$2.43B
| $345K | 0.22% |
+17,061
| New | +$345K |
|
192
Ligand Pharmaceuticals
LGND
$3.25B
| $344K | 0.22% |
4,818
+914
| +23% | +$65.3K |
|
|
SWTX
193
DELISTED
SpringWorks Therapeutics
SWTX
| $343K | 0.22% |
9,406
+5,816
| +162% | +$212K |
|
194
Ascendis Pharma
ASND
$12.5B
| $342K | 0.22% |
2,716
-652
| -19% | -$82.1K |
|
195
Amgen
AMGN
$153B
| $340K | 0.22% |
1,181
-198
| -14% | -$57K |
|
196
Travere Therapeutics
TVTX
$1.93B
| $340K | 0.22% |
37,798
+19,817
| +110% | +$178K |
|
197
Ultragenyx Pharmaceutical
RARE
$3.07B
| $340K | 0.22% |
7,105
+1,033
| +17% | +$49.4K |
|
198
Exelixis
EXEL
$10.2B
| $336K | 0.21% |
13,994
-2,207
| -14% | -$52.9K |
|
199
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $336K | 0.21% |
19,132
+671
| +4% | +$11.8K |
|
200
Alnylam Pharmaceuticals
ALNY
$59.2B
| $335K | 0.21% |
1,749
+216
| +14% | +$41.3K |
|